ARTICLE | Company News

Ember Therapeutics, Joslin Diabetes Center deal

April 2, 2012 7:00 AM UTC

The center granted Ember Therapeutics exclusive, worldwide rights to IP covering bone morphogenetic protein 7 ( BMP7; OP-1). The company said BMP7 has been shown to play a role in the regulation of brown fat development - brown fat burns calories to generate heat. Research investigating the role of BMP7 in brown fat was led in part by C. Ronald Kahn, one of Ember's co-founders. Details were not disclosed. ...